Benzene and Acute Myeloid Leukemia: Examining the Causal Link

From General Health Awareness to Occupational Exposure Concerns

Legacy health information resources have long provided the public with foundational knowledge on environmental hazards and their potential links to disease. In the domain of general health and science, these materials often address broad topics such as chemical safety, workplace hygiene, and chronic illness prevention. Within this context, benzene has been recognized as a substance of concern due to its widespread industrial use and documented toxicological profile. Transitioning from this general awareness to a more focused occupational perspective, it becomes necessary to examine how sustained exposure to benzene in specific work environments may elevate health risks. In mass production settings, particularly those involving chemical manufacturing, petroleum refining, and related industries, workers may encounter benzene as a solvent or intermediate compound. The shift from a general health framework to an occupational exposure concern highlights the importance of understanding the conditions under which benzene exposure occurs, including duration, concentration, and regulatory oversight. This transition does not require delving into specific disease mechanisms but rather acknowledges that the historical recognition of benzene as a hazardous agent has prompted targeted investigations into its role in the development of certain hematological conditions.

Benzene as a Recognized Cause of Acute Myeloid Leukemia

Benzene is a well-established cause of acute myeloid leukemia (AML), supported by epidemiological, mechanistic, and clinical evidence. Chronic exposure to benzene, a known myelotoxin, increases the risk of developing AML, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). Occupational exposure to benzene at levels of 10 ppm or more has been specifically associated with an increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). A meta-analysis of 25 studies found that benzene exposure was associated with an elevated risk of AML in children, with an odds ratio of 1.22 (95% CI: 1.02-1.46) per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/). Additionally, a large Swiss national cohort study confirmed that occupational benzene exposure is associated with elevated mortality risks for AML, as well as for diffuse large B-cell lymphoma and possibly follicular lymphoma (https://pubmed.ncbi.nlm.nih.gov/38727681/).

Clinical Presentation and Diagnosis of Benzene-Induced AML

The clinical presentation of AML includes symptoms such as fatigue, fever, easy bruising or bleeding, and recurrent infections, resulting from bone marrow failure and the accumulation of immature myeloid cells. Diagnosis is confirmed through complete blood count, peripheral blood smear, and bone marrow aspiration and biopsy, which reveal at least 20% blasts in the bone marrow or blood. Benzene-induced AML typically arises after a latency period that can range from several months to decades, depending on the intensity and duration of exposure. The timeline between benzene exposure and documented harm is variable, but occupational studies indicate that risk increases with cumulative exposure, and cases often emerge years after initial contact.

Mechanisms Linking Benzene to AML

Benzene is metabolized in the liver to reactive intermediates, such as benzene oxide, phenol, and hydroquinone, which are transported to the bone marrow. These metabolites cause genotoxic damage, including DNA strand breaks, chromosomal aberrations, and mutations in key genes involved in hematopoiesis, such as RUNX1, TP53, and FLT3. Mechanistic pathways linking benzene to AML include genotoxic effects, oxidative stress, inflammation, and immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). Epigenetic alterations, such as changes in DNA methylation and histone modification, also play a role in disrupting normal gene expression and promoting leukemogenesis. The mode of action for benzene-induced AML involves multiple key events, including hematotoxicity and genetic toxicity in peripheral blood, which can be observed in exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Preventing these early events would likely prevent the progression to AML and myelodysplastic syndromes.

Risk Considerations and Causation Assessment

Risk considerations for affected patients include the adequacy of warnings regarding benzene exposure and AML. While regulatory agencies have established occupational exposure limits, such as the U.S. Occupational Safety and Health Administration's permissible exposure limit of 1 ppm over an 8-hour workday, warnings may not always be sufficient to prevent harm, especially in settings with intermittent high exposures or inadequate monitoring. Causation-related considerations for patients diagnosed with AML after benzene exposure involve establishing a temporal relationship, ruling out other risk factors (e.g., prior chemotherapy, radiation, or genetic syndromes), and documenting exposure history. The latency period between benzene exposure and AML diagnosis is a critical factor in assessing causation, as shorter latencies may suggest higher cumulative exposure or individual susceptibility. In summary, benzene is a recognized cause of AML, with evidence from occupational cohorts, meta-analyses, and mechanistic studies. The risk is dose-dependent, and exposure levels as low as 1 μg/m³ have been associated with increased AML risk in children. Adequate warnings and exposure controls are essential to prevent benzene-induced hematologic malignancies.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does benzene cause acute myeloid leukemia?

Yes, benzene is a well-established cause of acute myeloid leukemia (AML). Epidemiological studies, including meta-analyses and cohort studies, have consistently shown an increased risk of AML following benzene exposure. For example, a meta-analysis of 25 studies found an elevated risk of AML in children with increasing benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/). Occupational studies also confirm that benzene exposure at levels of 10 ppm or more is associated with AML (https://pubmed.ncbi.nlm.nih.gov/33429013/).

What is the latency period between benzene exposure and AML?

The latency period between benzene exposure and the development of AML can range from several months to decades, depending on the intensity and duration of exposure. Occupational studies indicate that risk increases with cumulative exposure, and cases often emerge years after initial contact. Shorter latencies may suggest higher cumulative exposure or individual susceptibility.

How does benzene cause AML?

Benzene is metabolized in the liver to reactive intermediates such as benzene oxide, phenol, and hydroquinone, which are transported to the bone marrow. These metabolites cause genotoxic damage, including DNA strand breaks, chromosomal aberrations, and mutations in genes like RUNX1, TP53, and FLT3. Mechanistic pathways include genotoxic effects, oxidative stress, inflammation, and immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). Epigenetic alterations also play a role.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.